5 Key Takeaways
-
1
The FDA granted de novo marketing authorization for Notal Vision’s Scanly home OCT device for monitoring neovascular age-related macular degeneration.
-
2
Protocol AO compares home OCT-guided treatment with traditional treat-and-extend approaches to assess visual acuity and injection frequency over 104 weeks.
-
3
Home OCT may reduce treatment burden by allowing patients to extend intervals between injections based on remote monitoring of disease activity.
-
4
Daily monitoring with home OCT could lead to earlier detection of disease activity and facilitate personalized treatment for better patient outcomes.
-
5
Challenges in implementing home OCT include ensuring patient adherence to the technology for effective monitoring and treatment adjustments.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.